Recognizing Tardive Dyskinesia Symptoms from Reglan Use

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Occupational Exposure

If you or a loved one has been taking Reglan and notices involuntary movements, you may be seeing early signs of tardive dyskinesia. Decades of pharmacovigilance have established a clear link between metoclopramide and this neurological condition. This page reviews the published evidence on symptoms, risk factors, and clinical monitoring.

Understanding Reglan and Its Link to Tardive Dyskinesia

Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux and diabetic gastroparesis in adults. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved labeling for Reglan includes a boxed warning stating that metoclopramide can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning underscores the importance of using Reglan for the shortest duration necessary and periodically reassessing the need for continued therapy. Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The condition can be disfiguring and may persist even after discontinuation of the causative medication. According to the prescribing information, metoclopramide can also suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect complicates early detection and may allow the disorder to progress unnoticed. The mechanistic pathway linking Reglan to TD involves dopamine receptor blockade in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent abnormal motor control. While the exact pathophysiology is not fully understood, the clinical association is well-documented. The FDA label notes that Reglan is contraindicated in patients with a history of TD, and that immediate discontinuation is required if signs or symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Statute of Limitations for Reglan Claims in Illinois

For patients in Illinois considering legal action related to Reglan-induced TD, the statute of limitations is a critical factor. In Illinois, personal injury claims generally must be filed within two years of the date the injury was discovered or should have been discovered. This timeline can be challenging for TD patients, as symptoms may develop gradually and may not be immediately recognized as drug-related. The FDA label states that Reglan is indicated for treatment durations of 4 to 12 weeks for gastroesophageal reflux, and that longer-term use for diabetic gastroparesis should be avoided beyond 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, many patients have been prescribed Reglan for extended periods, increasing their risk of TD. Settlement considerations for affected patients often hinge on the adequacy of warnings provided by the manufacturer. The boxed warning on Reglan clearly states the risk of TD and the need for short-term use, but questions may arise about whether prescribers and patients were adequately informed of these risks prior to the warning's implementation. The timeline between exposure to Reglan and the onset of TD is variable; some patients develop symptoms within months, while others may not experience them until years later. This latency period can complicate the determination of when the statute of limitations begins to run. Patients who develop TD after using Reglan should seek medical evaluation to confirm the diagnosis and document the condition. Medical records should include details of Reglan use, including dosage and duration, as well as the onset and progression of symptoms. This documentation is essential for any potential legal claim. In Illinois, the statute of limitations may be subject to exceptions, such as the discovery rule, which delays the start of the limitations period until the injury is discovered or reasonably should have been discovered. However, courts may interpret this rule narrowly, and patients are advised to consult with an attorney promptly. The FDA label also warns that Reglan is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This is relevant for cases involving children, though most Reglan-related TD claims involve adults. In summary, the link between Reglan and tardive dyskinesia is well-established, with clear FDA warnings about the risks of prolonged use. For Illinois patients, the statute of limitations for filing a claim is generally two years from the discovery of the injury, but this timeline can be complex due to the delayed onset of TD. Affected individuals should seek legal counsel to understand their rights and the specific deadlines that apply to their case.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Illinois?

In Illinois, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. For tardive dyskinesia caused by Reglan, this timeline can be complex due to the delayed onset of symptoms. Patients should consult an attorney promptly to determine their specific deadline.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) can cause tardive dyskinesia through dopamine receptor blockade in the basal ganglia, leading to supersensitivity and abnormal motor control. The FDA label includes a boxed warning about this risk, which increases with duration of use and cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.